welcome to i-tech hiv/aids clinical seminar series 3 rd december 2009 women and hiv r. scott...
TRANSCRIPT
![Page 1: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/1.jpg)
Welcome to I-TECH HIV/AIDS Clinical Seminar Series
3rd December 2009
Women and HIV
R. Scott McClelland, MD, MPH
![Page 2: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/2.jpg)
Overview
• Introduction to HIV epidemiology in women
• HIV risk reduction for women
• Effect of male circumcision on the risk of HIV acquisition in female partners
• Gender-specific issues in selecting an antiretroviral regimen
![Page 3: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/3.jpg)
Percentage of Adults (15+) with HIV who are Women
UNAIDS Report 2008
![Page 4: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/4.jpg)
HIV in 15-25 year olds by sex
UNAIDS Report 2008
![Page 5: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/5.jpg)
Case 1: HIV Prevention
• 18 y.o. HIV-negative woman recently treated for gonorrhoeae. What proven strategies can reduce her risk of acquiring HIV?– A) Abstain, Be faithful, male latex Condoms– B) ABCs and treat STIs– C) Female condom– D) Pre-exposure prophylaxis– E) All of the above
![Page 6: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/6.jpg)
WHO Statement on HIV and STIs
WHO Fact Sheet on STI. Oct 2007 revision.
• Abstain from sexual intercourse
• Be faithful – Mutual long-term monogamy with HIV-negative partner
• Condoms
• Prompt treatment of STIs– Both in high risk and general population
![Page 7: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/7.jpg)
UNAIDS November 2009
New HIV infections reduced 17% over the past 8 years
![Page 8: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/8.jpg)
Condom Quiz
• How much do you know about condoms?
![Page 9: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/9.jpg)
Question 1
• With consistent and correct use of condoms, the estimated rate of pregnancy at 12 months is closest to which range?– A. 0%– B. 1-4%– C. 5-8%– D. 9-12%– E. Over 12%
WHO Fact Sheet No234. June 2000
![Page 10: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/10.jpg)
Question 1
• With consistent and correct use of condoms, the estimated rate of pregnancy at 12 months is closest to which range?– A. 0%– B. 1-4%– C. 5-8%– D. 9-12%– E. Over 12%
WHO Fact Sheet No234. June 2000
![Page 11: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/11.jpg)
Question 2
• For typical condom use, the estimated rate of pregnancy at 12 months is closest to which range?– A. 5-10%– B. 10-15%– C. 15-20%– D. Over 20%
WHO Fact Sheet No234. June 2000
![Page 12: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/12.jpg)
Question 2
• For typical condom use, the estimated rate of pregnancy at 12 months is closest to which range?– A. 5-10%– B. 10-15%– C. 15-20%– D. Over 20%
WHO Fact Sheet No234. June 2000
![Page 13: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/13.jpg)
Question 3
• Condom failure – the device breaking or slipping off completely during intercourse – is common.– A. True– B. False
WHO Fact Sheet No234. June 2000
![Page 14: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/14.jpg)
Condoms do not break easily
YouTube
![Page 15: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/15.jpg)
Condoms do not break easily
YouTube
![Page 16: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/16.jpg)
Question 4
• Longitudinal studies in men and women suggest that condoms reduce the risk of HIV infection by a rate that is closest to:– A. <50%– B. 50-65%– C. 65-80%– D. 80-95%– E. >95%
![Page 17: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/17.jpg)
Question 4
• Longitudinal studies in men and women suggest that condoms reduce the risk of HIV infection by a rate that is closest to:– A. <50%– B. 50-65%– C. 65-80%– D. 80-95%– E. >95%
![Page 18: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/18.jpg)
Question 5
• Longitudinal studies in women suggest that condoms reduce the risk of human papilloma virus (HPV) infection by at least:– A. 10%– B. 30%– C. 50%– D. 70%– E. 90%
Winer et al. N Engl J Med 2006
![Page 19: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/19.jpg)
Question 5
• Longitudinal studies in women suggest that condoms reduce the risk of human papilloma virus (HPV) infection by at least:– A. 10%– B. 30%– C. 50%– D. 70%– E. 90%
Winer et al. N Engl J Med 2006
![Page 20: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/20.jpg)
Case 1: HIV Prevention
• 18 y.o. HIV-negative woman at risk for HIV. Which microbicide has been associated with a trend towards decreased HIV risk?– A) Nonoxynol-9– B) SAVVY (C31G)– C) Cellulose Sulfate– D) Carragard– E) Buffer Gel– F) Pro 2000
![Page 21: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/21.jpg)
Case 1: HIV Prevention
• 18 y.o. HIV-negative woman at risk for HIV. Which microbicide has been associated with a trend towards decreased HIV risk?– A) Nonoxynol-9– B) SAVVY (C31G)– C) Cellulose Sulfate– D) Carragard– E) Buffer Gel– F) Pro 2000
![Page 22: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/22.jpg)
Microbicide
• Product that can be applied to vaginal or rectal mucosa with the intention of preventing or significantly reducing sexually transmitted infections including HIV infection– Gel– Ring– Film
![Page 23: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/23.jpg)
Possible Targets to Prevent Transmission of HIV
McGowan. Biologicals. 2006
![Page 24: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/24.jpg)
Pro2000 (Entry Inhibitor)
• 7 site study in Africa (6)/US (1)• 3099 women; 20.4 months; 93.6%
retention• Pro2000 vs. placebo HR 0.7 (95%CI 0.5-
1.1; p=0.10)• Pro2000 vs. no gel HR 0.7 (95%CI 0.4-
1.0; p=0.06)• Excluding time off product, Pro2000
reduced HIV incidence 36% (p=0.04)
Abdool Karim CROI 2009, LB48
![Page 25: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/25.jpg)
Microbicides in Clinical Trials
• Pro2000 study by British Microbicide Development Program– 0.5% Pro2000 ongoing– 2% Pro2000 arm closed by DSMB 2/2008
• Microbicides containing antiretrovirals; topical Pre-Exposure Prophylaxis– Tenofovir 1% gel (HPTN 059, CAPRISA, VOICE)– TMC 120 (IPM)– UC-781 (CONRAD)
![Page 26: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/26.jpg)
Case 1 Summary: HIV Prevention/Microbicides
• 18 y.o. HIV-seronegative woman has recently been treated for gonorrhea– ABCs and possibly other interventions such as
female condom may reduce HIV risk– Early microbicide trials with non-specific agents
generally not successful, but…– Recent experience with Pro2000 encouraging– Results of trials with antiretroviral-containing
microbicides are eagerly anticipated
![Page 27: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/27.jpg)
Case 2: Male Circumcision and the Risk of HIV Acquisition in Women
• An HIV-seropositive man is seeking circumcision.– Will circumcision influence the risk of HIV
transmission to his wife?
![Page 28: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/28.jpg)
Circumcision and HIV Transmission To Women
Quinn N Engl J Med 2000
![Page 29: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/29.jpg)
Circumcision of HIV-positive Men
Wawer. CROI 2008, 33LB
• Rakai study of 124 discordant couples with uninfected female partner
• Female partners tested every 6 months
![Page 30: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/30.jpg)
Circumcision in HIV-positive Men
• Reduced wound healing at 30 days compared to HIV-negative (73% vs. 83%, P<0.001)
• Less GUD in circumcised vs. uncircumcised arm of study (RR 0.48, 95% CI 0.3-0.8)
• Incidence in female partners; 14.4/100p-y in circumcised vs. 9.1/100p-y in uncircumcised (RR 1.59, 95%CI 0.7-4.3)
![Page 31: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/31.jpg)
Transmission by Timing of Wound Healing and Resumption of Sex
When sex resumed Intervention Arm
Transmitted/N
%
Before complete healing 5/18 27.8%
At or after complete healing
6/63 9.5%
Early vs. later RR=2.92 (1.01-8.46)
P=0.06
![Page 32: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/32.jpg)
Case 2 Summary: Male Circumcision and Risk of HIV Acquisition in Women
• An HIV-seropositive man is seeking circumcision. Will circumcision influence the risk of HIV transmission to his wife?– Transmission from an HIV-positive man to an
HIV-negative woman may be increased if sex is resumed before full wound healing
– Condom use must be promoted, especially during the period of wound healing
![Page 33: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/33.jpg)
Case 3: ART in Women
• 22 y.o. woman diagnosed with HIV during prior pregnancy. CD4=224cells/μL, HB=10g/dL, Ccreat = 100cc/min, other labs normal. On Depo Provera since first post-partum visit.– What other considerations should guide our decision about
the first-line ART regimen for this patient?
![Page 34: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/34.jpg)
Case 3: ART in Women
• 22 y.o. woman diagnosed with HIV during prior pregnancy. CD4=224cells/μL, HB=10g/dL, Ccreat = 100cc/min, other labs normal. On Depo Provera since first post-partum visit. She received single-dose nevirapine one year ago to reduce the risk of mother-to-child transmission of HIV during her first pregnancy.
![Page 35: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/35.jpg)
Case 3: ART in Women
• 22 y.o. woman diagnosed with HIV during prior pregnancy. CD4=224cells/μL, HB=10g/dL, Ccreat = 100cc/min, other labs normal. Started Depo Provera since first post-partum visit. She received single-dose nevirapine one year ago to reduce the risk of mother-to-child transmission of HIV during her first pregnancy. Which first-line ART regimen would you recommend:– A) Lopinavir/ritonavir + 2NRTI– B) Efavirenz or Nevirapine + 2NRTI– C) 3NRTI
![Page 36: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/36.jpg)
Case 3: ART in Women
• 22 y.o. woman diagnosed with HIV during prior pregnancy. CD4=224cells/μL, HB=10g/dL, Ccreat = 100cc/min, other labs normal. Started Depo Provera since first post-partum visit. She received single-dose nevirapine one year ago to reduce the risk of mother-to-child transmission of HIV during her first pregnancy. Which first-line ART regimen would you recommend:– A) Lopinavir/ritonavir + 2NRTI– B) Efavirenz or Nevirapine + 2NRTI BUT…– C) 3NRTI
![Page 37: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/37.jpg)
Consider Women’s History of Receiving Single Dose Nevirapine
No
Yes
No
* If no reproductive potential
Yes
![Page 38: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/38.jpg)
Response to Nevirapine Containing ART after sd-NVP for PMTCT
• 218 women starting ART after participation in a trial of NVP vs. placebo for PMTCT– 106 placebo and 112 sd-NVP women
• 6 months post ART initiation, virologic failure 5% in placebo vs. 18.4% in sd-NVP; p=0.002
• Within 6 months of sd-NVP– Failure 0% placebo vs. 41.7% sd-NVP; p<0.001
• Over 6 months after sd-NVP– Failure 7.8% placebo vs. 12% sd-NVP; p=0.39
Lockman NEJM 2007;356:135
![Page 39: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/39.jpg)
Time to Virologic Failure when ART Started <6 Months Post Partum
Lockman NEJM 2007;356:135
![Page 40: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/40.jpg)
Time to Virologic Failure when ART Started >6 Months Post Partum
Lockman NEJM 2007;356:135
![Page 41: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/41.jpg)
Time to Virologic Failure when ART Started >6 Months Post Partum
Lockman NEJM 2007;356:135
![Page 42: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/42.jpg)
Archived Resistance after PMTCT Regimens
• SD NVP leads to archiving of resistant HIV in latent CD4+ cells in >8% of women1
• Use of additional drugs reduces but doesn’t eliminate development of NVP resistance2,3
• Resistance to other components of regimen– Postpartum 3TC resistance (15% of exposed
women) associated with ~7-fold increased odds of 12-month virological failure in Cote d’Ivoire3
1. Wind-Rotolo. JID 20092. Lehman. JAIDS 20093. Coffie CID 2008.
![Page 43: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/43.jpg)
First-line Regimen Choice After SD Nevirapine
Aliv
e w
ithou
t V
irolo
gic
Fai
lure
0 25 50 75 100 125 150
Week
LPVr
NVP
Lockman. CROI Montreal February 2009
![Page 44: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/44.jpg)
Case 3 Summary: ART In Women
• Consider history of sd-NVP when selecting first-line ART regimen in women– If women received sd-NVP within past 6 months,
avoid all NNRTIs in first-line regimen– If women received sd-NVP >6 months prior to
ART initiation, okay include NNRTI in 1st line• Recommendations evolving with emerging data• Lamivudine resistance may also be an issue
– Higher adherence independently associated with improved outcome regardless of regimen1
1. Coffie CID 2008
![Page 45: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/45.jpg)
UNAIDS Report 2008
![Page 47: Welcome to I-TECH HIV/AIDS Clinical Seminar Series 3 rd December 2009 Women and HIV R. Scott McClelland, MD, MPH](https://reader035.vdocuments.us/reader035/viewer/2022081519/56649e705503460f94b6dfcc/html5/thumbnails/47.jpg)
Welcome to I-TECH HIV/AIDS Clinical Seminar Series
Next session: December 17, 2009
Devika Singh
HIV and STIs, Part 4